Rifampin Injection Shortage
Manufacturers report shortage status per product/package to the FDA independently, so the same generic drug can be short from one company while another still has supply -- the table below breaks that down company by company.
| Company | Brand name | Status | Last updated |
|---|---|---|---|
| Mylan Institutional, a Viatris Company | RIFAMPIN | Current | 09/03/2026 |
| Fresenius Kabi USA, LLC | RIFAMPIN | Current | 09/01/2026 |
| Sanofi-Aventis U.S. LLC | RIFADIN IV | Current | 06/22/2026 |